← All Vertex Pharmaceuticals INC / Ma filings

Vertex Pharmaceuticals INC / Ma 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
VRTX
Vertex Pharmaceuticals INC / Ma
10-K: Vertex Pharmaceuticals Reports Strong 2025 Revenue Growth, Advances Diverse Pipeline
Vertex Pharmaceuticals reported a 9% increase in total revenues to $12.0 billion in 2025, driven by strong demand for CF medicines and successful launches of CASGEVY and JOURNAVX, while advancing a diversified pipeline.
NASDAQ
VRTX
Vertex Pharmaceuticals INC / Ma
10-K: Vertex Pharmaceuticals Reports Strong 2024 Results, Advances Pipeline
Vertex Pharmaceuticals' 10-K filing highlights a successful year with increased revenue, new drug approvals, and progress in its diverse pipeline.
NASDAQ
VRTX
Vertex Pharmaceuticals INC / Ma
10-K: Vertex Pharmaceuticals Reports 2023 Financial Results and Provides Pipeline Update
Vertex Pharmaceuticals reports a strong 11% increase in net product revenues for 2023, driven by its cystic fibrosis franchise and prepares for potential launches in new therapeutic areas.